Paola Resende

Prof. Paola Resende

Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
Felipe NavecaFelipe Naveca
Felipe Naveca
VNValdinete Nascimento
Valdinete Nascimento
VSVictor Costa de Souza
Victor Costa de Souza
ACAndré de Lima Corado
André de Lima Corado
FNFernanda Nascimento
Fernanda Nascimento
GBGonzalo Bello
Gonzalo Bello
The northern state of Amazonas is among the regions in Brazil most heavily affected by the COVID-19 epidemic and has experienced two exponentially growing waves, in early and late 2020. Through a genomic epidemiology study based on 250 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from different Amazonas municipalities sampled between March 2020 and January 2021, we reveal that the first exponential growth phase was driven mostly by the dissemination of lineage B.1.195, which was gradually replaced by lineage B.1.1.28 between May and June 2020. The second wave coincides with the emergence of the variant of concern (VOC) P.1, which evolved from a local B.1.1.28 clade in late November 2020 and replaced the parental lineage in <2 months. Our findings support the conclusion that successive lineage replacements in Amazonas were driven by a complex combination of variable levels of social distancing measures and the emergence of a more transmissible VOC P.1 virus. These data provide insights to understanding the mechanisms underlying the COVID-19 epidemic waves and the risk of dissemination of SARS-CoV-2 VOC P.1 in Brazil and, potentially, worldwide.

16 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAnderson F. Brito
Anderson F. Brito
ESElizaveta Semenova
Elizaveta Semenova
GDGytis Dudas
Gytis Dudas
GHGabriel W. Hassler
Gabriel W. Hassler
CKChaney C. Kalinich
Chaney C. Kalinich
NFNuno Rodrigues Faria
Nuno Rodrigues Faria
Genomic sequencing is essential to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments, vaccines, and guide public health responses. To investigate the global SARS-CoV-2 genomic surveillance, we used sequences shared via GISAID to estimate the impact of sequencing intensity and turnaround times on variant detection in 189 countries. In the first two years of the pandemic, 78% of high-income countries sequenced >0.5% of their COVID-19 cases, while 42% of low- and middle-income countries reached that mark. Around 25% of the genomes from high income countries were submitted within 21 days, a pattern observed in 5% of the genomes from low- and middle-income countries. We found that sequencing around 0.5% of the cases, with a turnaround time <21 days, could provide a benchmark for SARS-CoV-2 genomic surveillance. Socioeconomic inequalities undermine the global pandemic preparedness, and efforts must be made to support low- and middle-income countries improve their local sequencing capacity.

9 June 2021 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
FKFrank Konings
Frank Konings
MPMark D. Perkins
Mark D. Perkins
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
MPMark Pallen
Mark Pallen
EAErik J. Alm
Erik J. Alm
MKMaria D. Van Kerkhove
Maria D. Van Kerkhove

26 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ABAnderson F. Brito
Anderson F. Brito
ESElizaveta Semenova
Elizaveta Semenova
GDGytis Dudas
Gytis Dudas
GHGabriel W. Hassler
Gabriel W. Hassler
CKChaney Kalinich
Chaney Kalinich
MKMaria van Kerkhove
Maria van Kerkhove
The COVID-19 pandemic has revealed the importance of virus genome sequencing to guide public health interventions to control virus transmission and understand SARS-CoV-2 evolution. As of July 20th, 2021, >2 million SARS-CoV-2 genomes have been submitted to GISAID, 94% from high income and 6% from low and middle income countries. Here, we analyse the spatial and temporal heterogeneity in SARS-CoV-2 global genomic surveillance efforts. We report a comprehensive analysis of virus lineage diversity and genomic surveillance strategies adopted globally, and investigate their impact on the detection of known SARS-CoV-2 virus lineages and variants of concern. Our study provides a perspective on the global disparities surrounding SARS-CoV-2 genomic surveillance, their causes and consequences, and possible solutions to maximize the impact of pathogen genome sequencing for efforts on public health. One-Sentence Summary The causes, consequences and possible solutions for disparities in genomic surveillance observed in the COVID-19 pandemic.

17 February 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
PRPaola Resende
Paola Resende
EDEdson Delatorre
Edson Delatorre
TGTiago Gräf
Tiago Gräf
DMDaiana Mir
Daiana Mir
FMFernando Couto Motta
Fernando Couto Motta
MSMarilda M. Siqueira
Marilda M. Siqueira
A previous study demonstrates that most of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Brazilian strains fell in three local clades that were introduced from Europe around late February 2020. Here we investigated in more detail the origin of the major and most widely disseminated SARS-CoV-2 Brazilian lineage B.1.1.33. We recovered 190 whole viral genomes collected from 13 Brazilian states from February 29 to April 31, 2020 and combined them with other B.1.1 genomes collected globally. Our genomic survey confirms that lineage B.1.1.33 is responsible for a variable fraction of the community viral transmissions in Brazilian states, ranging from 2% of all SARS-CoV-2 genomes from Pernambuco to 80% of those from Rio de Janeiro. We detected a moderate prevalence (5–18%) of lineage B.1.1.33 in some South American countries and a very low prevalence (<1%) in North America, Europe, and Oceania. Our study reveals that lineage B.1.1.33 evolved from an ancestral clade, here designated B.1.1.33-like, that carries one of the two B.1.1.33 synapomorphic mutations. The B.1.1.33-like lineage may have been introduced from Europe or arose in Brazil in early February 2020 and a few weeks later gave origin to the lineage B.1.1.33. These SARS-CoV-2 lineages probably circulated during February 2020 and reached all Brazilian regions and multiple countries around the world by mid-March, before the implementation of air travel restrictions in Brazil. Our phylodynamic analysis also indicates that public health interventions were partially effective to control the expansion of lineage B.1.1.33 in Rio de Janeiro because its median effective reproductive number (Re) was drastically reduced by about 66% during March 2020, but failed to bring it to below one. Continuous genomic surveillance of lineage B.1.1.33 might provide valuable information about epidemic dynamics and the effectiveness of public health interventions in some Brazilian states.

7 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
WDWanwisa Dejnirattisai
Wanwisa Dejnirattisai
JHJiandong Huo
Jiandong Huo
DZDaming Zhou
Daming Zhou
JZJiří Zahradník
Jiří Zahradník
PSPiyada Supasa
Piyada Supasa
GSGavin R Screaton
Gavin R Screaton
Summary: On the 24 th November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly in Southern Africa was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.